# Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions

> **NCT00845546** · NA · COMPLETED · sponsor: **Ranbaxy Laboratories Limited** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets

## Key facts

- **NCT ID:** NCT00845546
- **Lead sponsor:** Ranbaxy Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2002-08
- **Final completion:** 2002-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2009-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845546, "Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00845546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*